22666-84-8Relevant articles and documents
Application of novel pH sensitive isoniazid-heptamethine carbocyanine dye conjugates against prostate cancer cells
KONG, RUI-HENG,LI, YAN-FENG,WANG, DUN,WANG, YAN-JUN,YANG, XIAO-GUANG
, p. 412 - 416 (2020)
Recent studies have shown that monoamine oxidase A (MAOA) is significantly expressed in malignant prostate cancer (PCa) and plays an important role in tumorigenesis indicating its potential to serve as a target for PCa treatment. Here, we choose the small molecule isoniazid as the MAOA inhibition functionality and incorporated it in the tumor-targeting moiety of heptamethine carbocyanine dyes via a pH sensitive hydrazone bond to design and synthesize novel MAOA inhibitor isoniazid-heptamethine carbocyanine dye conjugates. Cytotoxicity assay in PC-3 cells shows that all conjugates possessed improved antitumor efficacy compared with isoniazid. The tested compounds also demonstrated a moderate MAOA inhibitory effect. In conclusion, these results indicate that these conjugates exert antitumor effects by delivering the MAOA-inhibiting moiety to PCa cells.
Synthesis of aromatic functionalized cage-rearranged silsesquioxanes (T8, T10, and T12) via nucleophilic substitution reactions
Chimjarn, Supansa,Kunthom, Rungthip,Chancharone, Prapassorn,Sodkhomkhum, Rapheepraew,Sangtrirutnugul, Preeyanuch,Ervithayasuporn, Vuthichai
supporting information, p. 916 - 919 (2015/02/19)
Organic-inorganic hybrid nano-building blocks of aromatic nitro-, aldehyde-, and bromo-functionalized polyhedral oligomeric silsesquioxanes were easily prepared through nucleophilic substitutions, starting from the reactions between octakis(3-chloropropyl)octasilsesquioxane and phenoxide derivatives. These phenoxide anions not only supply the substitution functions to a silsesquioxane cage, but can also induce a cage-rearrangement leading to the formation of octa-, deca-, and dodecahedral silsesquioxane cages. This journal is
Fused pyridine derivatives
-
Example 198, (2010/01/30)
The present provides a condensed pyridine compound (I) represented by the following formula: (wherein, R2represents ring A represents benzene ring, pyridine ring, thiophene ring or furan ring; and B represents its pharmaceutically acceptable salt or hydrates thereof, which is a clinically useful medicament having a serotonin antagonism, in particular, that for treating, ameliorating or preventing spastic paralysis or central muscle relaxants for ameliorating myotonia.